T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BBOT
1226
BridgeBio Oncology
BBOT
$712M
| $10.1M | ﹤0.01% |
803,134
-81,908
| -9% | -$992K |
|
|
CCCX
1227
DELISTED
Churchill Capital Corp X
CCCX
| $10M | ﹤0.01% |
+641,760
| New | +$10.8M |
|
1228
Dick's Sporting Goods
DKS
$18.1B
| $9.73M | ﹤0.01% |
49,151
+1,074
| +2% | +$234K |
|
1229
First Horizon
FHN
$12.4B
| $9.71M | ﹤0.01% |
406,297
+18,705
| +5% | +$417K |
|
1230
DT Midstream
DTM
$13.9B
| $9.66M | ﹤0.01% |
80,699
+1,775
| +2% | +$204K |
|
1231
Five Below
FIVE
$13.5B
| $9.58M | ﹤0.01% |
50,851
+3,394
| +7% | +$552K |
|
1232
Advanced Drainage Systems
WMS
$11.3B
| $9.57M | ﹤0.01% |
66,048
+7,365
| +13% | +$1.07M |
|
1233
Cars.com
CARS
$664M
| $9.56M | ﹤0.01% |
783,423
+4,626
| +0.6% | +$53.8K |
|
1234
Core Scientific
CORZ
$6.39B
| $9.5M | ﹤0.01% |
652,225
-3,705,717
| -85% | -$64.6M |
|
1235
Exelixis
EXEL
$12.5B
| $9.49M | ﹤0.01% |
216,417
-915,234
| -81% | -$37.9M |
|
|
WYFI
1236
WhiteFiber Inc
WYFI
$1.12B
| $9.49M | ﹤0.01% |
600,315
+24,189
| +4% | +$598K |
|
|
CMA
1237
DELISTED
Comerica
CMA
| $9.43M | ﹤0.01% |
108,421
+5,373
| +5% | +$432K |
|
1238
BioMarin Pharmaceuticals
BMRN
$13B
| $9.37M | ﹤0.01% |
157,579
+9,553
| +6% | +$520K |
|
1239
Root
ROOT
$793M
| $9.21M | ﹤0.01% |
127,435
+17,080
| +15% | +$1.36M |
|
1240
Essential Utilities
WTRG
$11.5B
| $9.07M | ﹤0.01% |
236,479
+17,424
| +8% | +$686K |
|
1241
United Parks & Resorts
PRKS
$2.05B
| $9.04M | ﹤0.01% |
249,013
+2,226
| +0.9% | +$92.5K |
|
1242
Korn Ferry
KFY
$4.3B
| $8.89M | ﹤0.01% |
134,682
+5,673
| +4% | +$382K |
|
|
GTLS
1243
DELISTED
Chart Industries
GTLS
| $8.86M | ﹤0.01% |
42,978
+1,465
| +4% | +$297K |
|
1244
AGNC Investment
AGNC
$13.1B
| $8.78M | ﹤0.01% |
818,683
+57,467
| +8% | +$591K |
|
1245
Ondas Inc
ONDS
$5.27B
| $8.76M | ﹤0.01% |
896,900
-523,483
| -37% | -$4.21M |
|
1246
Parsons
PSN
$5.07B
| $8.67M | ﹤0.01% |
140,311
+7,629
| +6% | +$597K |
|
|
CHYM
1247
Chime Financial
CHYM
$12.2B
| $8.67M | ﹤0.01% |
344,273
+137,041
| +66% | +$2.91M |
|
1248
Selective Insurance
SIGI
$5.58B
| $8.51M | ﹤0.01% |
101,743
+3,087
| +3% | +$248K |
|
1249
Jazz Pharmaceuticals
JAZZ
$15.9B
| $8.49M | ﹤0.01% |
49,960
+3,256
| +7% | +$499K |
|
1250
WSFS Financial
WSFS
$4.18B
| $8.47M | ﹤0.01% |
153,234
+76,524
| +100% | +$4.19M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.